Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Drug Profile

Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Alternative Names: MOG autologous T-lymphocyte cell therapy - ImCyse; MOG cytolytic CD4+ T-cell therapy - ImCyse; MOG gene therapy - ImCyse; MOG peptide gene therapy - ImCyse; MOG transduced T-cells - ImCyse; MOG-autologous CD4+ cell therapy - ImCyse; Myelin oligodendrocyte glycoprotein gene therapy - ImCyse; Myelin oligodendrocyte glycoprotein transduced T-cells - ImCyse

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator ImCyse
  • Developer GlaxoSmithKline; ImCyse
  • Class Anti-inflammatories; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunosuppressants; Myelin-oligodendrocyte glycoprotein expression stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Preclinical Asthma; Autoimmune disorders; Cancer; Graft-versus-host disease; Type 1 diabetes mellitus

Most Recent Events

  • 02 Mar 2016 ImCyse completes the SCLEROLYM phase II trial in Multiple sclerosis in Belgium (EudraCT2014-001081-99)
  • 23 Apr 2015 Preclinical trials in Autoimmune disorders in Belgium (unspecified route) prior to April 2015
  • 23 Apr 2015 Preclinical trials in Graft-versus-host disease in Belgium (unspecified route) prior to April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top